MYX mayne pharma group limited

Personal view, short selling won’t be a big problem for FY21 and...

  1. 124 Posts.
    lightbulb Created with Sketch. 22
    Personal view, short selling won’t be a big problem for FY21 and FY22. Obviously MYX is conservative about FDA approvals this time, as lessons learnt from last. Too risky to short when two big hits in the pipeline.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$5.08
Change
0.010(0.20%)
Mkt cap ! $412.7M
Open High Low Value Volume
$5.13 $5.15 $5.08 $445.2K 87.01K

Buyers (Bids)

No. Vol. Price($)
1 810 $5.08
 

Sellers (Offers)

Price($) Vol. No.
$5.15 2033 2
View Market Depth
Last trade - 16.10pm 27/06/2025 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.